Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Huya CEO Mireille Gingras On Partnering To Develop Chinese Compounds In The West: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

San Diego-based Huya Bioscience partners with Chinese research institutions and companies to identify preclinical and clinical-stage compounds, including traditional Chinese medicines to license for ex-China development. CEO Mireille Gingras recently spoke with PharmAsia News about Huya's partnership efforts in China. Prior to founding Huya, Gingras was founder and chief operating officer of MIR3, a software company developing online treatment programs for neuro-addictive diseases.

You may also be interested in...



INTERVIEW: Chipscreen CEO Bets Big On Chinese Innovation

When initial funding burned through and co-founders bailed out, Chipscreen CEO Lu Xianping faced the biggest challenge of his career. A firm belief in scientific evidence and an unwavering confidence in China-originated innovation helped him launch chidamide, a true made in China drug for a rare blood cancer, Lu told PharmAsia News in an exclusive interview.

Fresh Off Schering-Plough Deal, Huya Signs Pact With Beijing Institute To Open Bridge To Global Markets

BEIJING - Huya Bioscience International has signed a partnership agreement with the Beijing Institute of Materia Medica on joint development of innovative drugs that ultimately could help the institute penetrate the American and European markets, according to a senior Huya executive

Fresh Off Schering-Plough Deal, Huya Signs Pact With Beijing Institute To Open Bridge To Global Markets

BEIJING - Huya Bioscience International has signed a partnership agreement with the Beijing Institute of Materia Medica on joint development of innovative drugs that ultimately could help the institute penetrate the American and European markets, according to a senior Huya executive

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC069333

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel